Loading
A phase 1/2 trial in lung cancer, run by Xcovery Holdings, Inc., not yet recruiting.
BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) is a phase 1/2, interventional study registered as NCT05393466 by Xcovery Holdings, Inc., with a registry enrolment figure of 30 participants, started 2026-07-01 and due to reach its primary completion in 2028-01-30. Interventions recorded: BPI-361175. Conditions listed: Non-small Cell Lung Carcinoma. Primary outcome: The percentage of patients with adverse events and serious adverse events graded per National Cancer Institute Common Terminology Criteria for Adverse Events and dose limiting toxicities for BPI 361175; Efficacy of BPI-361175. Lung eligibility wording from the registry: "Patients with histologically or cytologically confirmed diagnosis of inoperable locally advanced or recurrent/metastatic NSCLC with EGFR mutations". No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.